European generics industry throws its weight behind IMPACT
This article was originally published in Scrip
Executive Summary
The emergence of counterfeit medicines in the European Union and indeed globally is a serious problem for the pharmaceutical industry. Generally counterfeiters target high-value products that are still under patent. However, fresh from the recent open forum on the World Health Organization's International Medical Products Anti-Counterfeiting Taskforce, in Geneva, Switzerland, Greg Perry, director general of the European Generic medicines Association, tells Faraz Kermani about his concerns relating to the effect of counterfeiting on the generics industry.